A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.
( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Stocktwits on MSN
IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week
The findings could play a key role in guiding treatment choices, ImmunityBio said. ・ImmunityBio will present new research on intravesical recombinant BCG in patients who have not previously received ...
National guidelines recommend adjuvant intravesical Bacillus Calmette-Guérin (BCG) therapy for higher-risk non–muscle-invasive bladder cancer (NMIBC). Although a survival benefit has not been ...
Learn everything you need to know about BCG live - Bacillus Calmette- Guerin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side ...
Intravesical therapy involving bacillus Calmette–Guérin (BCG) is standard of care for high-grade, noninvasive urothelial carcinoma, with reported cure rates higher than 70%. Systemic infection occurs ...
The Bacillus Calmette–Guérin vaccine (BCG) has been associated with beneficial nonspecific effects on infant health. We aimed to examine the effect of BCG at birth on thymic size and the associations ...
The concept of using Mycobacterium for cancer treatment goes back to the 19th Century. Today, bacillus Calmette–Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that is ...
Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results